Bax W A, Renzenbrink G J, van der Linden E A, Zijlstra F J, van Heuven-Nolsen D, Fekkes D, Bos E, Saxena P R
Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, The Netherlands.
Circulation. 1994 Feb;89(2):623-9. doi: 10.1161/01.cir.89.2.623.
The beneficial effect of low-dose aspirin in the prevention of coronary vasospasm is well documented. In this study, we investigated the contractile effect of human washed platelets on the human isolated coronary artery. We concentrated on the effect of low-dose aspirin (40 mg/d) taken by the platelet donor and on the efficacy of thromboxane A2 (TXA2) and 5-hydroxytryptamine (5-HT) receptor antagonists.
Human coronary artery segments were suspended in an organ bath set-up for isometric tension measurement. Platelets (10(9) to 3 x 10(10)/L) elicited concentration-dependent contractile responses of the coronary artery segments, reaching 28.4 +/- 7.1% of contractions induced by 100 mmol/L K+. The contractile response tended to be decreased in vessel segments with histological signs of early atherosclerosis. Contraction was significantly attenuated after pretreatment of the vessel segments with ketanserin (5-HT2 receptor antagonist, 1 mumol/L) or SQ30741 (TXA2 receptor antagonist, 0.01 mumol/L), reaching 8.8 +/- 2.3% and 3.2 +/- 2.2% of contraction to 100 mmol/L K+, respectively. Platelets obtained from the same platelet donors after they had taken aspirin (40 mg/d for 7 to 13 days) caused significantly lower contractile responses (7.6 +/- 2.7% of 100 mmol/L K+) associated with an almost selective inhibition of the synthesis of thromboxane measured in the organ bath solution (untreated platelets, 2.19 +/- 0.43 nmol/L; aspirin-treated platelets, 0.66 +/- 0.05 nmol/L). The amount of 5-HT secreted in the organ bath remained unaltered (65.17 +/- 9.94 and 64.03 +/- 8.98 nmol/L, respectively). This explains why ketanserin significantly attenuated the residual contractile responses caused by platelets obtained from aspirin-treated subjects, whereas SQ30741 caused minor, nonsignificant additional attenuation.
The results of the present study therefore suggest that additional antagonism of the contractile 5-HT receptors in the coronary artery may increase the efficacy of low-dose aspirin in vivo.
低剂量阿司匹林预防冠状动脉痉挛的有益作用已有充分文献记载。在本研究中,我们研究了人洗涤血小板对人离体冠状动脉的收缩作用。我们重点关注血小板供体服用低剂量阿司匹林(40mg/d)的效果以及血栓素A2(TXA2)和5-羟色胺(5-HT)受体拮抗剂的疗效。
将人冠状动脉节段悬挂于器官浴装置中以测量等长张力。血小板(10⁹至3×10¹⁰/L)引起冠状动脉节段浓度依赖性收缩反应,达到100mmol/L钾离子诱导收缩的28.4±7.1%。在有早期动脉粥样硬化组织学迹象的血管节段中,收缩反应倾向于降低。用酮色林(5-HT2受体拮抗剂,1μmol/L)或SQ30741(TXA2受体拮抗剂,0.01μmol/L)预处理血管节段后,收缩明显减弱,分别达到100mmol/L钾离子收缩的8.8±2.3%和3.2±2.2%。血小板供体服用阿司匹林(40mg/d,持续7至13天)后获得的血小板引起的收缩反应明显较低(为100mmol/L钾离子收缩的7.6±2.7%),且与器官浴溶液中测量的血栓素合成几乎选择性抑制相关(未处理的血小板,2.19±0.43nmol/L;阿司匹林处理的血小板,0.66±0.05nmol/L)。器官浴中分泌的5-HT量保持不变(分别为65.17±9.94和64.03±8.98nmol/L)。这解释了为什么酮色林能显著减弱阿司匹林处理受试者获得的血小板引起的残余收缩反应,而SQ30741引起的额外减弱较小且不显著。
因此,本研究结果表明,对冠状动脉中收缩性5-HT受体的额外拮抗作用可能会提高低剂量阿司匹林在体内的疗效。